FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308372409> ?p ?o ?g. }

• W4308372409 endingPage "117" @default.
• W4308372409 startingPage "108" @default.
• W4308372409 abstract "Background: Long-term outcomes of antiplatelet monotherapy in patients who receive percutaneous coronary intervention are unknown. The HOST-EXAM (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis–Extended Antiplatelet Monotherapy) Extended study reports the posttrial follow-up results of the original HOST-EXAM trial. Methods: From March 2014 through May 2018, 5438 patients who maintained dual antiplatelet therapy without clinical events for 12±6 months after percutaneous coronary intervention with drug-eluting stents were randomly assigned in a 1:1 ratio to receive clopidogrel (75 mg once daily) or aspirin (100 mg once daily). The primary end point (a composite of all-cause death, nonfatal myocardial infarction, stroke, readmission attributable to acute coronary syndrome, and Bleeding Academic Research Consortium type 3 or greater bleeding), secondary thrombotic end point (cardiac death, nonfatal myocardial infarction, ischemic stroke, readmission attributable to acute coronary syndrome, and definite or probable stent thrombosis), and bleeding end point (Bleeding Academic Research Consortium type 2 or greater bleeding) were analyzed during the extended follow-up period. Analysis was performed on the per-protocol population (2431 patients in the clopidogrel group and 2286 patients in the aspirin group). Results: During a median follow-up of 5.8 years (interquartile range, 4.8–6.2 years), the primary end point occurred in 12.8% and 16.9% in the clopidogrel and aspirin groups, respectively (hazard ratio, 0.74 [95% CI, 0.63–0.86]; P <0.001). The clopidogrel group had a lower risk for the secondary thrombotic end point (7.9% versus 11.9%; hazard ratio, 0.66 [95% CI, 0.55–0.79]; P <0.001) and secondary bleeding end point (4.5% versus 6.1%; hazard ratio, 0.74 [95% CI, 0.57–0.94]; P =0.016). There was no significant difference in the incidence of all-cause death between the 2 groups (6.2% versus 6.0%; hazard ratio, 1.04 [95% CI, 0.82–1.31]; P =0.742). Landmark analysis at 2 years showed that the beneficial effect of clopidogrel was consistent throughout the follow-up period. Conclusions: During an extended follow-up of >5 years after randomization, clopidogrel monotherapy compared with aspirin monotherapy was associated with lower rates of the composite net clinical outcome in patients without clinical events for 12±6 months after percutaneous coronary intervention with drug-eluting stents. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02044250." @default.
• W4308372409 created "2022-11-11" @default.
• W4308372409 creator A5000362954 @default.
• W4308372409 creator A5002085154 @default.
• W4308372409 creator A5004429865 @default.
• W4308372409 creator A5006372454 @default.
• W4308372409 creator A5009622965 @default.
• W4308372409 creator A5027776063 @default.
• W4308372409 creator A5028365408 @default.
• W4308372409 creator A5033807798 @default.
• W4308372409 creator A5044899608 @default.
• W4308372409 creator A5068077702 @default.
• W4308372409 creator A5081369231 @default.
• W4308372409 creator A5086488055 @default.
• W4308372409 creator A5088426143 @default.
• W4308372409 date "2023-01-10" @default.
• W4308372409 modified "2023-10-18" @default.
• W4308372409 title "Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy After Percutaneous Coronary Intervention: The HOST-EXAM Extended Study" @default.
• W4308372409 cites W1968837758 @default.
• W4308372409 cites W2007221451 @default.
• W4308372409 cites W2071335057 @default.
• W4308372409 cites W2165713946 @default.
• W4308372409 cites W2515533568 @default.
• W4308372409 cites W2560004679 @default.
• W4308372409 cites W2752033985 @default.
• W4308372409 cites W2758771548 @default.
• W4308372409 cites W2808265769 @default.
• W4308372409 cites W2809722890 @default.
• W4308372409 cites W2885843995 @default.
• W4308372409 cites W2916912835 @default.
• W4308372409 cites W2951424940 @default.
• W4308372409 cites W2973068166 @default.
• W4308372409 cites W3011371150 @default.
• W4308372409 cites W3083599811 @default.
• W4308372409 cites W311320695 @default.
• W4308372409 cites W3126709335 @default.
• W4308372409 cites W3163845177 @default.
• W4308372409 cites W4211143229 @default.
• W4308372409 cites W4225526112 @default.
• W4308372409 doi "https://doi.org/10.1161/circulationaha.122.062770" @default.
• W4308372409 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36342475" @default.
• W4308372409 hasPublicationYear "2023" @default.
• W4308372409 type Work @default.
• W4308372409 citedByCount "24" @default.
• W4308372409 countsByYear W43083724092022 @default.
• W4308372409 countsByYear W43083724092023 @default.
• W4308372409 crossrefType "journal-article" @default.
• W4308372409 hasAuthorship W4308372409A5000362954 @default.
• W4308372409 hasAuthorship W4308372409A5002085154 @default.
• W4308372409 hasAuthorship W4308372409A5004429865 @default.
• W4308372409 hasAuthorship W4308372409A5006372454 @default.
• W4308372409 hasAuthorship W4308372409A5009622965 @default.
• W4308372409 hasAuthorship W4308372409A5027776063 @default.
• W4308372409 hasAuthorship W4308372409A5028365408 @default.
• W4308372409 hasAuthorship W4308372409A5033807798 @default.
• W4308372409 hasAuthorship W4308372409A5044899608 @default.
• W4308372409 hasAuthorship W4308372409A5068077702 @default.
• W4308372409 hasAuthorship W4308372409A5081369231 @default.
• W4308372409 hasAuthorship W4308372409A5086488055 @default.
• W4308372409 hasAuthorship W4308372409A5088426143 @default.
• W4308372409 hasBestOaLocation W43083724091 @default.
• W4308372409 hasConcept C119060515 @default.
• W4308372409 hasConcept C126322002 @default.
• W4308372409 hasConcept C141071460 @default.
• W4308372409 hasConcept C164705383 @default.
• W4308372409 hasConcept C168563851 @default.
• W4308372409 hasConcept C203092338 @default.
• W4308372409 hasConcept C207103383 @default.
• W4308372409 hasConcept C2777628954 @default.
• W4308372409 hasConcept C2777698277 @default.
• W4308372409 hasConcept C2777849778 @default.
• W4308372409 hasConcept C2780400711 @default.
• W4308372409 hasConcept C2908647359 @default.
• W4308372409 hasConcept C44249647 @default.
• W4308372409 hasConcept C500558357 @default.
• W4308372409 hasConcept C71924100 @default.
• W4308372409 hasConcept C99454951 @default.
• W4308372409 hasConceptScore W4308372409C119060515 @default.
• W4308372409 hasConceptScore W4308372409C126322002 @default.
• W4308372409 hasConceptScore W4308372409C141071460 @default.
• W4308372409 hasConceptScore W4308372409C164705383 @default.
• W4308372409 hasConceptScore W4308372409C168563851 @default.
• W4308372409 hasConceptScore W4308372409C203092338 @default.
• W4308372409 hasConceptScore W4308372409C207103383 @default.
• W4308372409 hasConceptScore W4308372409C2777628954 @default.
• W4308372409 hasConceptScore W4308372409C2777698277 @default.
• W4308372409 hasConceptScore W4308372409C2777849778 @default.
• W4308372409 hasConceptScore W4308372409C2780400711 @default.
• W4308372409 hasConceptScore W4308372409C2908647359 @default.
• W4308372409 hasConceptScore W4308372409C44249647 @default.
• W4308372409 hasConceptScore W4308372409C500558357 @default.
• W4308372409 hasConceptScore W4308372409C71924100 @default.
• W4308372409 hasConceptScore W4308372409C99454951 @default.
• W4308372409 hasFunder F4320322557 @default.
• W4308372409 hasIssue "2" @default.
• W4308372409 hasLocation W43083724091 @default.
• W4308372409 hasLocation W43083724092 @default.
• W4308372409 hasOpenAccess W4308372409 @default.

• next